Skip to main content
SpringerLink
Log in

Novel Therapies for Psoriasis

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

The T cell-driven immunopathogenesis of psoriasis has been well recognized since cyclosporine first revolutionized the treatment of psoriasis 20 years ago. Almost all investigative and clinical research subsequently, has concentrated on elucidating the specifics of antigen presentation, T cell interaction and the production of specific cytokines. The role of the keratinocyte, previously thought to be the primary target cell in psoriasis pathogenesis, has been relegated to a secondary role and the mechanism of action of systemic methotrexate in psoriasis has been challenged, the primary role of the T lymphocyte is now well known.

While psoriasis has traditionally been treated ‘ab initio’ with topical medications (corticosteroids, vitamin D3, and retinoid derivatives), either singly, in combination, or with ultraviolet B (UVB) or psoralens and ultraviolet A (PUVA) therapy, the role of systemic medications has assumed greater prominence. Thus, three systemic medications currently are approved worldwide for the treatment of moderate to severe forms of psoriasis, namely cyclosporine, methotrexate and acitretin. The first two are likely to give significant clearing (greater than 75%) in the majority of cases, whereas acitretin is significantly less effective as monotherapy, but may approach methotrexate and cyclosporine in efficacy, if combined with PUVA or UVB phototherapy. The main limitations of these three drugs remain organ toxicity, especially hepatic toxicity with methotrexate, hypertension and nephrotoxicity with cyclosporine, and teratogenecity and mucocutaneous toxicity with acitretin. Thus, the need for more specific systemic therapy, targeting the T lymphocyte. This has become the major area of clinical research interest over the past 5 years, with the promise of longer-term disease control (improved remissions) and less organ toxicities. Currently, there are over 15 of these ‘biologic’ drugs in various stages of development and clinical trials, either by the subcutaneous, intramuscular or intravenous route. The three main variables are the rapidity of onset, percentages of improvement and remission rates. Without exception, these new systemic agents appear to be remarkably free of systemic organ toxicities (liver, renal, bonemarrow, etc.), with adverse effects being limited to mild flu-like symptoms with the anticipated increase in infections (e.g., herpes simplex) being either equal to placebo or only marginally increased. Not all these agents under evaluation give clinical responses equal to methotrexate or cyclosporine (75% or greater clearing in 75% of cases). In addition, response rates may be slower with some therapies versus others. However, the need for intermittent administration even by the injectable route, longer remissions, lack of systemic organ toxicities and the potential for safer usage in females of child-bearing age, make a compelling argument for widespread acceptance by both patients and the dermatological community. Other modalities under clinical evaluation include vitamin D and retinoid drugs, topically and systemically, with effects on nuclear receptors, as well as more specific wavelengths (308 to 311nm) of UVB phototherapy with application for more localized forms of psoriasis. For the 2 to 3% of the worldwide population of patients with psoriasis the future has never looked brighter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Nickoloff B.J., Fivenson D.P., Kunkel S.L., et al. Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 1994; 73 (1): 63–8

    Article  PubMed  CAS  Google Scholar 

  2. Reich K., Hilmes D., Middel P., et al. Treatment of psoriasis with IL-10 downregulates the epidermal interleukin-8/CXCR2 pathway [abstract]. Br J Dermatol 1999; 141: 980

    Article  Google Scholar 

  3. Asadullah K.S.W., Stephanek K., Jasulaitis D., et al. IL-10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy, a new therapeutic approach. J Clin Invest 1998; 101 (4): 783–94

    Article  PubMed  CAS  Google Scholar 

  4. Nickoloff B.J., Mitra R.S., Varani J., et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144: 820–8

    PubMed  CAS  Google Scholar 

  5. Bhushan M., McLaughlin B., Weiss J.B., et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054–60

    Article  PubMed  CAS  Google Scholar 

  6. Linden K.G., Weinstein G.D. Use of methotrexate in psoriasis. Dermatol Ther 1999; 11: 52–9

    Google Scholar 

  7. Genestier L., Paillot R., Fournel S., et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322–8

    Article  PubMed  CAS  Google Scholar 

  8. Paillot R., Genestier L., Fournel S., et al. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 1998; 30: 2348–50

    Article  PubMed  CAS  Google Scholar 

  9. Boffa M.J., Chalmers R.J. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399–408

    Article  PubMed  CAS  Google Scholar 

  10. Collins P., Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol 1992; 17: 257–60

    Article  PubMed  CAS  Google Scholar 

  11. Ryan T.J., Baker H. Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis: evaluation and prognosis based on study of 104 cases. Br J Dermatol 1969; 81: 134–45

    Article  PubMed  CAS  Google Scholar 

  12. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466–9

    Article  PubMed  CAS  Google Scholar 

  13. Epinette W.W., Parker C.M., Jones E.L., et al. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17: 962–71

    Article  PubMed  CAS  Google Scholar 

  14. Marinari R., Fleischmajer R., Schragger A.H., et al. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 1977; 113: 930–2

    Article  PubMed  CAS  Google Scholar 

  15. Jones E.L., Epinette W.W., Hackney V.C., et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537–42

    Article  PubMed  CAS  Google Scholar 

  16. Lynch W.S., Roenigk H.H. Mycophenolic acid for psoriasis. Arch Dermatol 1977; 113: 1203–8

    Article  PubMed  CAS  Google Scholar 

  17. Haufs M.G., Beissert S., Grabbe S., et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138 (1): 179–81

    Article  PubMed  CAS  Google Scholar 

  18. Hood K.A., Zarembski D.G. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Heath Syst Pharm 1997; 54 (3): 285–94

    CAS  Google Scholar 

  19. Zackheim H.S., Glogau R.G., Fisher D.A., et al. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994; 30 (3): 452–8

    Article  PubMed  CAS  Google Scholar 

  20. Murphy F.P., Coven T.R., Burack L.H., et al. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol 1999; 135 (12): 1495–502

    Article  PubMed  CAS  Google Scholar 

  21. Molin L., Thomsen K. Thioguanine treatment in psoriasis. Acta Derm Venereol (Stockh) 1987; 67 (1): 85–8

    CAS  Google Scholar 

  22. Silvis N.G., Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol 1999; 135 (4): 433–7

    Article  PubMed  CAS  Google Scholar 

  23. Boyd A.S., Neldner K.H. Hydroxyurea therapy. J Am Acad Dermatol 1991; 25 (3): 518–24

    Article  PubMed  CAS  Google Scholar 

  24. Cather J.C., Abramovits W., Menter A.M. Cyclosporine and tacrolimus use in dermatology. Dermatol Clin 2001; 19 (1): 119–37

    Article  PubMed  CAS  Google Scholar 

  25. Mrowietz U., Ruzicka T. Cyclosporine A for psoriasis. Dermatol Ther 1999; 11: 60–6

    Google Scholar 

  26. Mueller W., Herrmann B. Cyclosporine A for psoriasis [letter]. N Engl J Med 1979; 301: 555

    PubMed  CAS  Google Scholar 

  27. Powles A.V., Hardman C.M., Porter W.M., et al. Renal function after 10 years’ treatment with cyclosporine for psoriasis. Br J Dermatol 1998; 138: 443–9

    Article  PubMed  CAS  Google Scholar 

  28. Grassberger M., Baumruker T., Enz A., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141 (2): 264–73

    Article  PubMed  CAS  Google Scholar 

  29. Meingassner J.G., Grassberger M., Farngruber H., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo. Br J Dermatol 1997; 137: 568–76

    Article  PubMed  CAS  Google Scholar 

  30. Mrowietz U., Graeber M., Brautigam M., et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992–6

    Article  PubMed  CAS  Google Scholar 

  31. Paul C., Graeber M., Stuetz A., et al. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000 Jan; 9 (1): 69–77

    Article  CAS  Google Scholar 

  32. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102: 555–7

    Article  PubMed  CAS  Google Scholar 

  33. Lauerma A.I., Surber C., Maibach H.I. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporine A. Skin Pharmacol 1997; 10 (5–6): 230–4

    Article  PubMed  CAS  Google Scholar 

  34. Lauerma A.I., Maibach H.I. Topical FK506: clinical potential or laboratory curiosity? Dermatology 1994; 188: 173–6

    Article  PubMed  CAS  Google Scholar 

  35. Zonneveld I.M., Rubins A., Jablonska S., et al. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Arch Dermatol 1998; 134 (9): 1101–2

    Article  PubMed  CAS  Google Scholar 

  36. Yamamoto S., Kato R. Hair growth-stimulating effects of cyclosporine A and FK506, potent immunosuppressants. J Dermatol Sci 1994; 7Suppl.: S47–54

    Article  PubMed  CAS  Google Scholar 

  37. Remitz A., Reitamo S., Erkko P., et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141 (1): 103–7

    Article  PubMed  CAS  Google Scholar 

  38. Jegasothy B.V., Ackerman C.D., Todo S., et al. Tacrolimus (FK 506): a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781–5

    Article  PubMed  CAS  Google Scholar 

  39. The European FK 506 Multicenter Psoriasis Study Group Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebocontrolled study. Arch Dermatol 1996; 132: 419–23

    Article  Google Scholar 

  40. Nikolaidis N., Abu-Elmagd K., Thomson A.W., et al. Metabolic effects of FK506 in patients with severe psoriasis: short term follow-up of seven patients. Transplant Proc 1991; 23 (6): 3325–7

    PubMed  CAS  Google Scholar 

  41. Coven T.R., Walters I.B., Cardinale I., et al. PUVA-induced lymphocyte apoptosis: mechanism of action in psoriasis. Photodermatol Photoimmunol Photomed 1999; 15 (1): 22–7

    Article  PubMed  CAS  Google Scholar 

  42. Ozawa M., Ferenczi K., Kikuchi T., et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189 (4): 711–8

    Article  PubMed  CAS  Google Scholar 

  43. Coven T.R., Murphy F.P., Gilleaudeau P., et al. Trimethylpsoralen bath PUVA is a remittive treatment for psoriasis vulgaris: evidence that epidermal immunocytes are direct therapeutic targets. Arch Dermatol 1998; 134 (10): 1263–8

    Article  PubMed  CAS  Google Scholar 

  44. Walters I.B., Burack L.H., Coven T.R., et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40 (6 Pt 1): 893–900

    Article  PubMed  CAS  Google Scholar 

  45. van Weelden H., Baart de la Faille H., Young E., et al. Comparison of narrow-band UVB phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol (Stockh) 1990; 70: 212–5

    Google Scholar 

  46. Bolognia J.L., Freije L., Amici L., et al. Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulations. J Am Acad Dermatol 1996; 35: 424–7

    Article  PubMed  CAS  Google Scholar 

  47. Pham C.T., Koo J.Y. Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol 1993; 28 (3): 460–6

    Article  PubMed  CAS  Google Scholar 

  48. Tanew A., Ortel B., Rappersberger K., et al. 5-Methoxypsoralen (Bergapten) for photochemotherapy: bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. J Am Acad Dermatol 1988; 18 (2 Pt 1): 333–8

    Article  PubMed  CAS  Google Scholar 

  49. Calzavara-Pinton P., Ortel B., Carlino A., et al. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Exp Dermatol 1992; 1 (1): 46–51

    Article  PubMed  CAS  Google Scholar 

  50. Berg M., Ros A.M. Treatment comparison with psoralens and ultraviolet A: a doubleblind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994; 10 (5): 217–20

    PubMed  CAS  Google Scholar 

  51. Aubin F., Makki S., Humbert P., et al. Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation. Arch Dermatol Res 1994; 286 (1): 30–4

    Article  PubMed  CAS  Google Scholar 

  52. Walchner M., Rocken M. Topical treatment regimens: PUVA. Dermatol Ther 1999; 11: 37–45

    Google Scholar 

  53. Koo J., Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41 (1): 51–9

    Article  PubMed  CAS  Google Scholar 

  54. Vallat V.P., Gilleaudeau P., Battat L., et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180 (1): 283–96

    Article  PubMed  CAS  Google Scholar 

  55. Asawanonda P., Anderson R.R., Chang Y., et al. 308-nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000; 136 (5): 619–24

    Article  PubMed  CAS  Google Scholar 

  56. Bonis B., Kemeny L., Dobozy A., et al. 308 nm UVB excimer laser for psoriasis [letter]. Lancet 1997; 350 (9090): 1522

    Article  PubMed  CAS  Google Scholar 

  57. Elder J.T., Astrom A., Pettersson U., et al. Differential regulation of retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992; 98: 673–9

    Article  PubMed  CAS  Google Scholar 

  58. Elder J.T., Fisher G.J., Zhang Q.Y., et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol 1991; 96: 425–33

    Article  PubMed  CAS  Google Scholar 

  59. Carlberg C., Saurat J.H. Vitamin D-retinoid association: molecular basis and clinical applications. J Invest Dermatol 1996; 1 (1): 82–6

    CAS  Google Scholar 

  60. Franz T.J., Parsell D.A., Myers J.A., et al. Clobetasol propionate foam 0.05 %: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39 (7): 535–8

    Article  PubMed  CAS  Google Scholar 

  61. Feldman S.R., Sangha N., Setaluri V. Topical corticosteroid in foam vehicle offers comparable coverage compared to traditional vehicles. J Am Acad Dermatol 2000; 42 (6): 1017–20

    Article  PubMed  CAS  Google Scholar 

  62. Franz T.J., Parsell D.A., Halualani R.M., et al. Betamethasone valerate foam.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38 (8): 628–32

    Article  PubMed  CAS  Google Scholar 

  63. Kang S.Y.S., Griffiths C.E., Fancher L., et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138 (1): 77–83

    Article  PubMed  CAS  Google Scholar 

  64. Michel G., Gailis A., Jarzebska-Deussen B., et al. 1,25-(OH)-vitamin D3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells. Inflamm Res 1997; 46 (1): 32–4

    Article  PubMed  CAS  Google Scholar 

  65. van de Kerkhof P.C.M., Berth-Jones J., Bunker C., et al. A multicentre, open, prospective study to investigate the long-term safety and efficacy of tacalcitol in nonhospitalised patients with psoriasis. Br J Dermatol 1999; 141: 989–90

    Google Scholar 

  66. Barker J.N., Ashton R.E., Marks R., et al. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141 (2): 274–8

    Article  PubMed  CAS  Google Scholar 

  67. Tang-Liu D.D., Matsumoto R.M., Usansky J.I. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999; 37 (4): 273–87

    Article  PubMed  CAS  Google Scholar 

  68. Marks R. Clinical safety of tazarotene in the treatment of plaque psoriasis. J Am Acad Dermatol 1997; 37 (2 Pt 3): S25–32

    Article  PubMed  CAS  Google Scholar 

  69. Esgleyes-Ribot T., Chandraratna R.A., Lew-Kaya D.A., et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994; 30 (4): 581–90

    Article  PubMed  CAS  Google Scholar 

  70. Weinstein G.D., Krueger G.G., Lowe N.J., et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85–92

    Article  PubMed  CAS  Google Scholar 

  71. Lebwohl M., Ast E., Callen J.P., et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38: 705–11

    Article  PubMed  CAS  Google Scholar 

  72. Hoffmann M., Herde M., Altmeyer P., et al. Relationship between skin type and initial irritative side-effects of tazarotene therapy [abstract]. Br J Dermatol 1999; 141: 991

    Article  Google Scholar 

  73. Kang S., Voorhees J.J. Retinoids in psoriasis. Dermatol Ther 1999; 11: 67–74

    Google Scholar 

  74. Gronhoj Larsen F., Steinkjer B., Jakobsen P., et al. Acitretin is converted to etretinate only during concomitant alcohol intake. Br J Dermatol 2000 Dec; 143 (6): 1164–9

    Article  Google Scholar 

  75. Gottlieb S., Hayes E., Gilleaudeau P., et al. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996; 23 (5): 404–18

    Article  PubMed  CAS  Google Scholar 

  76. Berth-Jones J., Todd G., Itutchinson P.E., et al. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol 2000; 143: 1170–6

    Article  PubMed  CAS  Google Scholar 

  77. Miller V.A., Benedetti F.M., Rigas J.R., et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15 (2): 790–7

    PubMed  CAS  Google Scholar 

  78. Smit J., de Jong E., van Hooijdonk C., et al. A multicentre phase II clinical and immunohistochemical trial of oral bexarotene in patients with moderate to severe plaque psoriasis [abstract]. J Invest Dermatol 2000; 114: 776

    Google Scholar 

  79. Bexarotene package insert. La Jolla (CA): Ligand Pharmaceuticals, 2002

  80. Weinstein G.D. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454–9

    Article  PubMed  CAS  Google Scholar 

  81. Menter A., See J.A., Amend J.C., et al. Proceedings of the psoriasis combination and rotation therapy conference. J Am Acad Dermatol 1996; 34: 315–21

    Article  PubMed  CAS  Google Scholar 

  82. Menter M.A., Abramovits W. Rational, sequential and combination regimens in the treatment of psoriasis [abstract]. Dermatol Ther 1999; 11: 88–95

    Google Scholar 

  83. Lebwohl M., Siskins B., Epinette W., et al. A multicenter trial of calcipotreine ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268–9

    Article  PubMed  CAS  Google Scholar 

  84. Lebwohl M., Breneman D.L., Goffe B.S., et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 39: 590–6

    Article  PubMed  CAS  Google Scholar 

  85. Speight E.L., Farr P.M. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994; 130: 79–82

    Article  PubMed  CAS  Google Scholar 

  86. Shuster S., Marks J.M., Lawerence C.M. Retinoids and PUVA in psoriasis. Br J Dermatol 1985; 112: 122–3

    Article  PubMed  CAS  Google Scholar 

  87. Barker J.N.W.N., Griffiths C.E.M. Combination therapy for psoriasis. Dermatol Ther 1999; 11: 96–103

    Google Scholar 

  88. Koo J. Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with phototherapy: a review. J Am Acad Dermatol 1997; 37 (3 Pt 2): S59–61

    PubMed  CAS  Google Scholar 

  89. Molin L. Topical calcipotriol combined with phototherapy for psoriasis: the results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology 1999; 198 (4): 375–81

    Article  PubMed  CAS  Google Scholar 

  90. Kokelj F., Lavaroni G., Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venereol (Stockh) 1995; 75: 386–7

    CAS  Google Scholar 

  91. McKenna K.E., Stern R.S. Photosensitivity associated with combined UVB and calcipotriene therapy. Arch Dermatol 1995; 131: 1323–4

    Article  Google Scholar 

  92. Youn J.L., Park B.S., Chung J.H., et al. Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. Photodermatol Photoimmunol Photomed 1997; 13: 109–14

    Article  PubMed  CAS  Google Scholar 

  93. Kokelj F., Lavaroni G., Perkan V., et al. Hyperpigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients. Acta Derm Venereol (Stockh) 1995; 75: 307–9

    CAS  Google Scholar 

  94. Glaser R., Rowert J., Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 1998; 139: 148–51

    Article  PubMed  CAS  Google Scholar 

  95. Koo J.Y. Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998; 39 (4 Pt 2): S144–9

    Article  PubMed  CAS  Google Scholar 

  96. Koo J.Y., Lowe N.J., Lew-Kaya D.A., et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000; 43 (5): 821–8

    Article  PubMed  CAS  Google Scholar 

  97. Fritsch P., Honigsmann H., Jaschke E., et al. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol 1978; 70: 178–82

    Article  PubMed  CAS  Google Scholar 

  98. Grupper C., Berretti B. Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason). Dermatologica 1981; 162: 404–13

    Article  PubMed  CAS  Google Scholar 

  99. Lowe N.J., Prystowsky J., Armstrong R.B. Acitretin plus UVB therapy for psoriasis. J Am Acad Dermatol 1991; 4: 591–4

    Article  Google Scholar 

  100. Ruzicka T., Somerberg C., Braun-Falco O., et al. Efficiency of acitretin in combination with UVB in the treatment of severe psoriasis. Arch Dermatol 1990; 126: 482–6

    Article  PubMed  CAS  Google Scholar 

  101. Lane-Brown M. 5-Methoxypsoralen, etretinate, and UVA for psoriasis. Int J Dermatol 1987; 26 (10): 655–9

    Article  PubMed  CAS  Google Scholar 

  102. Molin L., Larko O. Cancer induction by immunosuppression in psoriasis after heavy PUVA treatment [letter]. Acta Derm Venereol (Stockh) 1997; 77: 402

    CAS  Google Scholar 

  103. Van de Kerkhof P.C.M., De Rooij M.J.M. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporine treatment: response to long-term acitretin maintenance. Br J Dermatol 1997; 136: 275–8

    Article  PubMed  Google Scholar 

  104. Morison W.L., Momtaz K., Parrish J.A., et al. Combination methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 6: 46–51

    Article  PubMed  CAS  Google Scholar 

  105. MacKie R.M., Fitzsimons C.P. Risk of carcinogenicity in patients with psoriasis treated with methotrexate or PUVA singly or in combination. J Am Acad Dermatol 1983; 9: 467–9

    Article  PubMed  CAS  Google Scholar 

  106. Tugwell P., Pincus T., Yocum D., et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137–41

    Article  PubMed  CAS  Google Scholar 

  107. Stein C.M., Pincus T., Yocum D., et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. Arthritis Rheum 1997; 40: 1843–51

    Article  PubMed  CAS  Google Scholar 

  108. Clark C.M., Kirby B., Morris A.D., et al. Combination treatment with methotrexate and cyclosporine for severe recalcitrant psoriasis. Br J Dermatol 1999; 141 (2): 279–82

    Article  PubMed  CAS  Google Scholar 

  109. Kirby B., Harrison P.V. Combination low-dose cyclosporine (Neoral) and hydroxyurea for severe recalcitrant psoriasis. Br J Dermatol 1999; 140 (1): 186–7

    Article  PubMed  CAS  Google Scholar 

  110. van der Kerkhof P.C., Cambazard F., Hutchinson P.E., et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84–9

    Article  PubMed  Google Scholar 

  111. van der Rhee H.J., Tijssen J.G.P., Herrmann W.A., et al. Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: a double blind trial. Br J Dermatol 1980; 102: 203–12

    Article  PubMed  Google Scholar 

  112. Orfanos C.E., Runne U. Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis. Br J Dermatol 1976; 95: 101–3

    Article  PubMed  CAS  Google Scholar 

  113. Polano M.K., van der Rhee H.J., van der Schroeff J.G. A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically. Acta Derm Venereol (Stockh) 1982; 62: 361–4

    CAS  Google Scholar 

  114. Salomon D., Mesheit J., Masgrau-Peya E., et al. Acetretin does not prevent psoriasis relapse related to cyclosporine A tapering. J Am Acad Dermatol 1994; 130: 257–8

    CAS  Google Scholar 

  115. Tuyp E., MacKie R.M. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol 1986; 14: 70–3

    Article  PubMed  CAS  Google Scholar 

  116. Zachariae H. Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis [letter]. Arch Dermatol 1984; 120: 155

    Article  PubMed  CAS  Google Scholar 

  117. Beck H.I., Foged E.K. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica 1983; 167: 94–6

    Article  PubMed  CAS  Google Scholar 

  118. Asadullah K., Sabat R., Wiese A., et al. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999; 291 (12): 628–36

    Article  PubMed  CAS  Google Scholar 

  119. Asadullah K., Sterry W., Ebeling M., et al. Clinical and immunological effects of IL-10 therapy in psoriasis [abstract]. Br J Dermatol 1999; 141: 989

    Article  Google Scholar 

  120. Seifert M., Sterry W., Effenberger E., et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 2000; 292 (4): 164–72

    Article  PubMed  CAS  Google Scholar 

  121. Asadullah K., Docke W.D., Ebeling M., et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999; 135 (2): 187–92

    Article  PubMed  CAS  Google Scholar 

  122. Trepicchio W.L., Ozawa M., Walters I.B., et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104 (11): 1527–37

    Article  PubMed  CAS  Google Scholar 

  123. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356 (9227): 385–90

    Article  PubMed  CAS  Google Scholar 

  124. Antoni C., Dechant C., Lorenz H., et al. Successful treatment of severe psoriatic arthritis with infliximab [abstract]. Arthritis Rheum 1999; 42 (9 Suppl.): S371

    Google Scholar 

  125. Oh C.J., Das K.M., Gottleeb A.B., et al. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000 May; 42 (5 Pt 1): 829–30

    Article  PubMed  CAS  Google Scholar 

  126. Lohner M., Krueger J., Gottlieb A., et al. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis [abstract]. Br J Dermatol 1999; 141 (5): 989

    Google Scholar 

  127. Mirmohammadsadegh A., Homey B., Abts H.F., et al. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide. Biochem Pharmacol 1998; 55 (9): 1523–9

    Article  PubMed  CAS  Google Scholar 

  128. Kuypers T.W., Roos D. Leukocyte membrane adhesion receptors LFA-1, CR3, and p150,95: a review of functional and regulatory aspects. Res Immunol 1989; 140: 461–86

    Article  PubMed  CAS  Google Scholar 

  129. Bos J.D. Psoriasis: immunological facts and speculations [abstract]. Br J Dermatol 1999; 135: 830

    Google Scholar 

  130. Papp K.A., Bissonette R., Goldwater R., et al. The treatment of moderate to severe psoriasis with hu1124: a new monoclonal antibody [abstract]. Br J Dermatol 1999; 141 (5): 980

    Google Scholar 

  131. Gottlieb A., Miller B., Chaudhari U., et al. Clinical and histologic effects of subcutaneously administered anti-CD11a (hu1124) in patients with psoriasis [abstract]. J Invest Dermatol 2000; 114 (4): 840

    Google Scholar 

  132. Kreuger J.G., Papp K., Gottlieb A.B., et al. Administration of humanised CD11A antibodies (hu1124) to psoriasis patients blocks LFA-1 expression and reverses diseases defining pathology [abstract]. Br J Dermatol 1999; 141 (5): 994

    Google Scholar 

  133. Gottlieb A.B., Krueger J., Ahsan A., et al. Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11A monoclonal antibody (hu1124): results of a multicenter, multiple ascending dose study [abstract]. Arthritis Rheum 1999; 42 (9 Suppl.): S373

    Google Scholar 

  134. Gottlieb A., Krueger J., Abdulghani A., et al. Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11a monoclonal antibody (hu1124): results of a multicenter, multiple ascending dose study [abstract]. J Invest Dermatol 1999; 112 (4): 647

    Google Scholar 

  135. Magilavy D. Amevive Clinical Study Group. Immunopharmacologic effects of Amevive (LFA3-TIP) in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naive (CD45RA+) T cells [abstract]. Br J Dermatol 1999; 141 (5): 990

    Google Scholar 

  136. Magilavy D., Mant T., Norman P., et al. Pharmacodynamic effects of LFA3-TIP (Amevive) in patients with chronic plaque psoriasis (CPP): selective modulation of CD45RO+ lymphocytes [abstract]. J Invest Dermatol 1999; 112 (4): 609

    Google Scholar 

  137. Ellis C. Amevive Clinical Study Group. Quality of life (QOL) of Amevive (LFA3-TIP) in patients with chronic plaque psoriasis [abstract]. Br J Dermatol 1999; 141 (5): 990–1

    Google Scholar 

  138. Magilavey D., Krueger G.G. The response of chronic plaque psoriasis to Amevive (LFA3-TIP) and the selective suppression of peripheral memory/effector T Cells (CD45RO+) versus naive T cells (CD45RA+) is linked to serum levels of LFA3-TIP [abstract]. J Invest Dermatol 2000; 114 (4): 776

    Google Scholar 

  139. Krueger G. Amevive Clinical Study Group. Phase II trial results of Amevive (LFA3-TIP) in patients with chronic plaque psoriasis [abstract]. Br J Dermatol 1999; 141 (5): 979–80

    Google Scholar 

  140. Rogge M., Ellis C., Krueger G., et al. Pharmacokinetics of LFA3-TIP (Amevive) in chronic plaque psoriasis patients during repeated once-weekly intravenous administration [abstract]. J Invest Dermatol 1999; 112 (4): 608

    Google Scholar 

  141. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4-Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103 (9): 1243–52

    Article  PubMed  CAS  Google Scholar 

  142. Abrams J.R., Kelley S.L., Hayes E., et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192 (5): 681–94

    Article  PubMed  CAS  Google Scholar 

  143. Krueger J.G., Walters I.B., Miyazawa M., et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43 (3): 448–58

    Article  PubMed  CAS  Google Scholar 

  144. Owen C.M., Harrison P.V. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25 (3): 195–7

    Article  PubMed  CAS  Google Scholar 

  145. Deckert F., Legay F. Development and validation of an immunoreceptor assay for simulect based on surface plasmon resonance. Analytical Biochem 1999; 274 (1): 81–9

    Article  CAS  Google Scholar 

  146. Gottlieb A.B., Lebwohl M., Shirin S., et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43 (4): 595–604

    Article  PubMed  CAS  Google Scholar 

  147. Gottlieb A., Abdulghani A., Totoritis M., et al. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis [abstract]. J Invest Dermatol 2000; 114 (4): 840

    Google Scholar 

  148. Ferenczi K., Burack L., Pope M., et al. CD69, HLA-DR, and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14 (1): 63–78

    Article  PubMed  CAS  Google Scholar 

  149. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB-389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442–7

    Article  PubMed  CAS  Google Scholar 

  150. Bagel J., Garland W.T., Breneman D., et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938–44

    Article  PubMed  CAS  Google Scholar 

  151. Collins P., Robinson D.J., Stringer M.R., et al. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1997 Nov; 137 (5): 743–9

    Article  PubMed  CAS  Google Scholar 

  152. Robinson D.J., Collins P., Stringer M.R., et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999 Nov; 79 (6): 451–5

    Article  PubMed  CAS  Google Scholar 

  153. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. Sem Oncology 1994; 21 (6 Suppl. 15): 11–4

    CAS  Google Scholar 

  154. Dupont E., Savard P.E., Jourdain C., et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998; 2 (3): 146–52

    PubMed  CAS  Google Scholar 

  155. Gulliver W.P., Adams M., Farrand D., et al. Peptide-T: a novel neuro peptide analog for the treatment of psoriasis [abstract]. Br J Dermatol 1999; 141: 969–1000

    Google Scholar 

  156. Janssen N.M., Genta M.S. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Int Med 2000; 160 (5): 610–9

    Article  CAS  Google Scholar 

  157. Morris L., Harrod M., Menter M.A., et al. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993; 29: 913–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Jennifer Cather is in receipt of a grant from Baylor University Medical Center, Dallas. Alan Menter has nil funding except for administration. Authors have performed clinical research studies for Genentech, Biogen, Idec, Abgenix, Allergan, Immunex, Centocor and Ligand.

Author information

Authors and Affiliations

  1. Baylor University Medical Center, 5310 Harvest Hill Road, Suite 260, Dallas, Texas, 75230, USA

    Jennifer Cather &  Alan Menter

Authors
  1. Jennifer Cather
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Menter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan Menter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cather, J., Menter, A. Novel Therapies for Psoriasis. Am J Clin Dermatol 3, 159–173 (2002). https://doi.org/10.2165/00128071-200203030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200203030-00003

Keywords

Search

Navigation